Phase III clinical trial for treatment of dry eye syndrome* Plus the latest pharma industry news & events

18 FEBRUARY 2019 | NEWSLETTER #8

THIS WEEK'S TOP STORIES

Phase III clinical trial for treatment of dry eye syndrome A Phase III trial looks to treat dry eye syndrome using a sterile, preservative-free eye drop formulation that has thymosin beta 4 as its active ingredient…

SMC accepts restricted use of rivaroxaban for CAD The SMC has approved a drug, called rivaroxaban, that targets Factor Xa to treat those with coronary artery disease (CAD)…

Advancing the application of artificial intelligence to health A collaboration between Brigham and Women’s Hospital and Vanderbilt University Medical Center looks to advance the application of AI in health…

NICE and Canadian Agency collaborate to offer parallel scientific advice  NICE in the UK and its counterpart – the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice…

FDA launches pilot programme to track and trace US supply chain The pilot project will test innovative and emerging approaches for enhanced tracing and verification of prescription drugs in the US…

Phase III combination trial improves survival in men with metastatic prostate cancer A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy, with enzalutamide…